ANGLE PLC

Legal Proceedings Report • Aug 4, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0970O

Angle PLC

04 August 2014

For immediate release	4 August 2014

ANGLE plc

("ANGLE" or "the Company")

PARSORTIX GRANTED SECOND US PATENT

ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that it has been granted a second United States Patent for its Parsortix system, which captures rare cells in blood for medical analysis.

This is the second patent covering the Parsortix system and has been filed under Number 8,765,456 B2, entitled "Microstructure for Particle and Cell Separation, Identification, Sorting, and Manipulation".

The second patent strengthens the claims regarding the core Parsortix technology protected by the first patent. Corresponding patent applications have been made worldwide in countries considered to represent substantial markets for Parsortix products and are in process.

The second patent protects aspects of design, manufacture and deployment of the Parsortix cell separation equipment including:

·     concepts concerning the core separation technology

·     different types of separation structure design, materials and manufacturing methods

·     mechanisms of cell separation such as degree of cell deformability, or interaction between cell surface and device construction materials

·     treatment of construction materials or components with reagents such as antibodies to enable specialised separations

·     methods to harvest captured target cells (i.e. recovering them from a separation device after capture so they can be used for subsequent analysis, diagnosis, culture or fractionation)

·     priming processes to prepare separation devices for use in routine processes (for example to remove air bubbles)

·     use of separation devices in combination (for example multiple devices linked in parallel for simultaneous separations of several blood samples)

·     separation of specific cell types including foetal cells and stem cells in addition to circulating tumour cells

·     cell detection, identification and analysis directly on separation devices after capture

·     extraction of macromolecules from cells captured on separation devices for analysis. 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"The grant of our second US patent gives ANGLE broader protection over the Parsortix separation technology.  We are pursuing a strategy to strengthen the breadth and duration of our patent coverage to maximise the commercial returns that can be achieved from our Parsortix technology."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSSSFMFFLSEEA